Cassaday & Co Wealth Management
PCVX icon

Cassaday & Co Wealth Management’s Vaxcyte PCVX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2
Closed -$117 – 1418
2026
Q2 		$117 Hold
2
– – ﹤0.01% 1258
2026
Q1 		$117 Buy
+2
New +$109 ﹤0.01% 1320

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Cassaday & Co Wealth Management's PCVX Position: Q3 2026 in Review

Cassaday & Co Wealth Management sold out of Vaxcyte (PCVX) in Q3 2026, closing a stake of 2 shares — an estimated $117 sold.

Cassaday & Co Wealth Management first reported a position in PCVX in Q1 2026 and held it in 2 quarters. The position peaked at $117 in Q2 2026. 167 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Cassaday & Co Wealth Management reported no remaining Vaxcyte position as of Q3 2026 after selling out during the quarter.
  • Cassaday & Co Wealth Management sold 2 Vaxcyte shares in Q3 2026, an estimated $117.
  • Cassaday & Co Wealth Management first reported a position in Vaxcyte in Q1 2026 and held it in 2 quarters.
  • Cassaday & Co Wealth Management's Vaxcyte position peaked at $117 in Q2 2026.
  • 167 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.